Inventiva S.A. (NASDAQ: IVA) has revealed the half-year report of its liquidity contract with Kepler Cheuvreux. Inventiva has earned a reputation as a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the cure of NASH, MPS, and other diseases with significant unfulfilled medical needs.
As per the liquidity contract awarded by Inventiva to Kepler Cheuvreux, the resources which were available in the liquidity account as of December 31, 2021, include € 761,542.29 Cash, 45,462 shares, 1,253 executions on the buy-side on the semester, and 1,425 executions on the sell-side on the semester. It also includes 209,935 shares for € 2,438,368.87 traded volume on the buy-side on the semester and 211,076 shares for € 2,510,782.11 traded volume on the sell-side on the semester.
Furthermore, the resources which were available in the liquidity account at the last half-year report as of June 30, 2021, includes € 689,129.05 Cash, 46,603 shares, 1,511 executions on the buy-side on the semester, 1,435 executions on the sell-side on the semester, 289,008 shares for € 3,547,633.77 traded volume on buy-side on the semester, 257,898 shares for € 3,208,144.47 traded volume on sell-side on the semester.
Additionally, when the contract was initially executed, the resources which were in the liquidity account included € 163,510.42 Cash and 34,063 shares.